142 related articles for article (PubMed ID: 7548701)
21. Design of phase II trials in congestive heart failure.
DeMets DL
Am Heart J; 2000 Apr; 139(4):S207-10. PubMed ID: 10740134
[No Abstract] [Full Text] [Related]
22. Sequential methods for comparing years of life saved in the two-sample censored data problem.
Murray S; Tsiatis AA
Biometrics; 1999 Dec; 55(4):1085-92. PubMed ID: 11315052
[TBL] [Abstract][Full Text] [Related]
23. Item response models for joint analysis of quality of life and survival.
Wang C; Douglas J; Anderson S
Stat Med; 2002 Jan; 21(1):129-42. PubMed ID: 11782055
[TBL] [Abstract][Full Text] [Related]
24. Changing frequency of interim analysis in sequential monitoring.
Lan KK; DeMets DL
Biometrics; 1989 Sep; 45(3):1017-20. PubMed ID: 2790114
[TBL] [Abstract][Full Text] [Related]
25. Interim analysis for randomized clinical trials: simulating the predictive distribution of the log-rank test statistic.
Chang MN; Shuster JJ
Biometrics; 1994 Sep; 50(3):827-33. PubMed ID: 7981402
[TBL] [Abstract][Full Text] [Related]
26. Digoxin in heart failure.
Chadwell M; French L
J Fam Pract; 1997 May; 44(5):442. PubMed ID: 9152256
[No Abstract] [Full Text] [Related]
27. A logrank test-based method for sizing clinical trials with two co-primary time-to-event endpoints.
Sugimoto T; Sozu T; Hamasaki T; Evans SR
Biostatistics; 2013 Jul; 14(3):409-21. PubMed ID: 23307913
[TBL] [Abstract][Full Text] [Related]
28. Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.
Horiguchi M; Hassett MJ; Uno H
Clin Trials; 2020 Dec; 17(6):597-606. PubMed ID: 32933339
[TBL] [Abstract][Full Text] [Related]
29. Concomitant use of a positive inotropic agent to create a bridge to the successful initiation of beta-blocker therapy in patients with heart failure: a proposal for a trial.
Zampino M; O'Connor CM; Gattis WA; Adams KF; Gheorghiade M
Am Heart J; 2003 Feb; 145(2 Suppl):S62-6. PubMed ID: 12594456
[No Abstract] [Full Text] [Related]
30. Information growth for sequential monitoring of clinical trials with a stepped wedge cluster randomized design and unknown intracluster correlation.
Brown SP; Shoben AB
Clin Trials; 2020 Apr; 17(2):176-183. PubMed ID: 32026713
[TBL] [Abstract][Full Text] [Related]
31. Review of a dose-dependent increase in mortality with vesnarinone among patients with severe heart failure.
LeJemtel TH
Curr Cardiol Rep; 1999 May; 1(1):31. PubMed ID: 10980817
[No Abstract] [Full Text] [Related]
32. A flexible and coherent test/estimation procedure based on restricted mean survival times for censored time-to-event data in randomized clinical trials.
Horiguchi M; Cronin AM; Takeuchi M; Uno H
Stat Med; 2018 Jul; 37(15):2307-2320. PubMed ID: 29682762
[TBL] [Abstract][Full Text] [Related]
33. Overview of the DIG trial.
Collins JF; Egan D; Yusuf S; Garg R; Williford WO; Geller N;
Control Clin Trials; 2003 Dec; 24(6 Suppl):269S-276S. PubMed ID: 14643073
[TBL] [Abstract][Full Text] [Related]
34. Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis.
Lueza B; Rotolo F; Bonastre J; Pignon JP; Michiels S
BMC Med Res Methodol; 2016 Mar; 16():37. PubMed ID: 27025706
[TBL] [Abstract][Full Text] [Related]
35. Adaptive trial design: a general methodology for censored time to event data.
Jahn-Eimermacher A; Ingel K
Contemp Clin Trials; 2009 Mar; 30(2):171-7. PubMed ID: 19130902
[TBL] [Abstract][Full Text] [Related]
36. Estrogen is associated with improved survival in aging women with congestive heart failure: analysis of the vesnarinone studies.
Reis SE; Holubkov R; Young JB; White BG; Cohn JN; Feldman AM
J Am Coll Cardiol; 2000 Aug; 36(2):529-33. PubMed ID: 10933368
[TBL] [Abstract][Full Text] [Related]
37. Current perspectives on the design of phase II trials of new drugs for the treatment of heart failure.
Packer M
Am Heart J; 2000 Apr; 139(4):S202-6. PubMed ID: 10740133
[No Abstract] [Full Text] [Related]
38. Duration of accrual and follow-up for two-stage clinical trials.
Case LD; Morgan TM
Lifetime Data Anal; 2001 Mar; 7(1):21-37. PubMed ID: 11280845
[TBL] [Abstract][Full Text] [Related]
39. Sequential conditional probability ratio tests for normalized test statistic on information time.
Xiong X; Tan M; Boyett J
Biometrics; 2003 Sep; 59(3):624-31. PubMed ID: 14601763
[TBL] [Abstract][Full Text] [Related]
40. A two-stage procedure for survival studies with surrogate endpoints.
Flandre P; O'Quigley J
Biometrics; 1995 Sep; 51(3):969-76. PubMed ID: 7548712
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
